NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
Abstract Cancer immunoediting drives the adaptation of tumor cells to host immune surveillance. Previously, we have demonstrated that immunoediting driven by cytotoxic T lymphocytes (CTLs) enriches NANOG+ tumor cells with immune-refractory properties. Here, we found that CTL-mediated immune pressure...
Main Authors: | Sung Wook Son, Eunho Cho, Hanbyoul Cho, Seon Rang Woo, Hyo-Jung Lee, Se Jin Oh, Suyeon Kim, Jae-Hoon Kim, Eun Joo Chung, Joon-Yong Chung, Min Gyu Kim, Kwon-Ho Song, Tae Woo Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-12692-6 |
Similar Items
-
Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
by: Se Jin Oh, et al.
Published: (2022-03-01) -
The roles of NANOG in tumorigenesis
by: Jinchul Kim, et al.
Published: (2018-05-01) -
579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle
by: Tae Woo Kim, et al.
Published: (2023-11-01) -
TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway
by: Se Jin Oh, et al.
Published: (2023-05-01) -
Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer
by: Ji-Won Ryu, et al.
Published: (2023-03-01)